July 2026– date –
-
Sana Biotechnology Announces Groundbreaking 14-Month Durability Data for Hypoimmune-Modified Islet Cell Transplantation (UP421) in Type 1 Diabetes Without Immunosuppression, Published in The New England Journal of Medicine
GlobeNewswire (Sana Biotechnology) USA Overview Sana Biotechnology announced groundbreaking long-term durability data for its hypoimmune-modified islet cell transplant UP421 in Type 1 Diabetes patients, demonstrating 14 months of sustain... -
Beyond RNA: DNA-Guided CRISPR Heralds a New Era of Precision Gene Editing
Liv Hospital Turkey Overview Liv Hospital reports a significant shift in CRISPR gene editing, moving from conventional RNA-guided to potentially more stable and precise DNA-guided systems. This evolution, coupled with advancements in del... -
Space-Grown Organoids and Proteomics Synergize to Advance Human Disease Research for Complex Conditions like Retrosyndromes and Cancer
Scientific News Outlet USA Overview On July 17, 2026, the fusion of space-grown organoids and proteomics technology was reported to be significantly advancing research into complex human diseases such as retrosyndromes and cancer. Organo... -
NIH-Funded Team Discovers Miniaturized CRISPR Enzyme Al3Cas12f, Enabling Precision In Vivo Gene Delivery via AAV Vectors
National Institutes of Health (NIH) USA Overview An NIH-funded research team has discovered a novel, enhanced miniaturized CRISPR gene-editing system, a natural enzyme named 'Al3Cas12f,' capable of targeted in vivo delivery. This enzyme ... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
Century Therapeutics Unveils Preclinical Data for iPSC-Derived Islet Replacement Therapy CNTY-813 for Type 1 Diabetes, Aiming for Immunosuppression-Free Treatment via Allo-Evasion™ 5.0 Technology and H2 2026 IND Filing
GlobeNewswire (Century Therapeutics) USA Overview Century Therapeutics announced that preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, will be presented at EASD 2026 and the Breakthrough T1D ... -
CAR T-Cell Therapy Broadens Horizons: Expanding Indications and Manufacturing Advances Drive Wider Access Beyond Oncology to Autoimmune Diseases
AJMC USA Overview This review article comprehensively discusses how CAR T-cell therapy is entering an era of broader adoption, driven by clinical advancements, expanding indications, and enhanced manufacturing efficiency. Building on ini... -
FDA Regenerative Medicine Advanced Therapy (RMAT) Designations Hit Record High of 48 in 2025, Accounting for 48% of All Designations in Past Two Years
PharmaLive USA Overview According to a GlobalData report, the number of Regenerative Medicine Advanced Therapy (RMAT) designations granted by the FDA reached a record-breaking 48 in 2025, with designations in 2024 and 2025 collectively a... -
ISSCR to Host iPSC 20th Anniversary Symposium in Kyoto, Japan in October 2026, Celebrating Two Decades of Breakthrough Science
International Society for Stem Cell Research (ISSCR) Japan Overview The International Society for Stem Cell Research (ISSCR) announced a symposium in Kyoto, Japan, in October 2026, commemorating the 20th anniversary of iPSC discovery. Th... -
U.S. FDA RMAT Designations Surge to 165 Total, with Rocket Pharmaceuticals (5) and CRISPR Therapeutics (4) Leading the Way
BioInformant USA Overview As of July 15, 2026, the cumulative number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 165. Rocket Pharmaceuticals and CRISPR Therapeutics are not...
